Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Cr Pharmaceutical
Pharmaceutical Preparation ManufacturingHong Kong SAR China
Last verified 1 month agocrpharm.com
Cr Pharmaceutical, officially known as China Resources Pharmaceutical Group Limited, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Hong Kong. Established in 1992, the company has made significant strides in the healthcare sector, focusing on the development, production, and distribution of a wide range of pharmaceutical products.
With a strong presence in major operational regions across China and beyond, Cr Pharmaceutical is renowned for its innovative drug formulations and high-quality healthcare solutions. The company’s core offerings include prescription medications, over-the-counter products, and traditional Chinese medicines, distinguished by their commitment to research and development.
Recognised for its market leadership, Cr Pharmaceutical has achieved numerous accolades, solidifying its reputation as a trusted name in the pharmaceutical industry. Its dedication to quality and innovation continues to drive its success in meeting the evolving needs of healthcare providers and patients alike.
39
DitchCarbon score
-3 vs industry average
Cr Pharmaceutical’s score of 39 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Cr Pharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2028
202020212022202320242025202620272028
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Cr Pharmaceutical's reported carbon emissions
CR Pharmaceutical, headquartered in HK and operating in the Pharmaceutical Preparation Manufacturing industry, reported Scope 1 emissions of 172,130,250 kg CO2e and Scope 2 emissions of 568,741,300 kg CO2e for 2025. This data is cascaded from its parent company, China Resources Pharmaceutical Group Limited.
The company has set several climate commitments:
- Carbon Neutrality: CR Pharmaceutical aims to achieve carbon neutrality for Scope 1 and Scope 2 emissions by 2050. This long-term goal for Scope 1 and Scope 2 emissions was established in 2023.
- Emissions Intensity Reduction Targets:
- Scope 2: By the end of the 14th Five-Year Plan period (2025), CR Pharmaceutical aims to reduce carbon dioxide emission intensity by 10% compared to 2020 levels.
- Scope 1: By the end of the 14th Five-Year Plan period (2025), the company targets an 8% decrease in comprehensive energy consumption per RMB 10,000 of added value, relative to 2020.
In previous years, CR Pharmaceutical reported the following Scope 1 and Scope 2 emissions (where available):
- 2024: Scope 1 emissions were 175,023,130 kg CO2e, and Scope 2 emissions were 547,436,670 kg CO2e.
- 2023: Scope 1 emissions were 170,536,140 kg CO2e, and Scope 2 emissions were 555,112,180 kg CO2e.
- 2022: Total Scope 1 and Scope 2 emissions were approximately 722,459,800 kg CO2e, comprising 160,986,950 kg CO2e from Scope 1 and 613,993,650 kg CO2e from Scope 2.
- 2021: Total Scope 1 and Scope 2 emissions were approximately 648,394,790 kg CO2e, with 121,763,870 kg CO2e from Scope 1 and 526,630,920 kg CO2e from Scope 2.
- 2020: Combined Scope 1 and Scope 2 emissions were approximately 540,802,560 kg CO2e.
- 2019: Combined Scope 1 and Scope 2 emissions were approximately 560,123,090 kg CO2e.
- 2018: Combined Scope 1 and Scope 2 emissions were approximately 541,956,860 kg CO2e.
- 2017: Scope 1 emissions were 513,058,290 kg CO2e, which was also reported as the combined Scope 1 and Scope 2 total.
- 2016: Scope 1 emissions were 527,962,720 kg CO2e, which was also reported as the combined Scope 1 and Scope 2 total.
Scope 3 emissions data for purchased goods and services was not available for any reported year.
Assessing Cr Pharmaceutical as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Cr Pharmaceutical and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Cr Pharmaceutical’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
On track94%
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
At risk48%
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Behind target22%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Cr Pharmaceutical1 month ago
39
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more